Alpha‐Synuclein as a Biomarker for Parkinson's Disease

Staging of brain pathology related to sporadic Parkinson’s disease

Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

MDS clinical diagnostic criteria for Parkinson’s disease

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653

Parkinson's disease: clinical features and diagnosis

Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720

Overdependence on degraded gist memory in Alzheimer's disease.

Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110

Clinical diagnostic criteria for dementia associated with Parkinson’s disease

Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027

α-Synuclein is phosphorylated in synucleinopathy lesions

Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174

Parkinson's Disease

Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072

A systematic review of prevalence studies of dementia in Parkinson's disease

Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

Zeissler, M., Li, V., Parmar, M., & Carroll, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191856 · Cited by 24

Common aspects between glaucoma and brain neurodegeneration

Saccà, S. C., Paluan, F., Gandolfi, S., Manni, G., Cutolo, C. A., & Izzotti, A. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108323 · Cited by 25

Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using α-Synuclein and External Anal Sphincter Electromyography

Cao, Z., Wu, Y., Liu, G., Jiang, Y., Wang, X., Wang, Z., & Feng, T. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01043 · Cited by 24

Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients

Bhumkar, A., Magnan, C., Lau, D., Jun, E. S. W., Dzamko, N. L., Gambin, Y., & Sierecki, E. (2021) · Angewandte Chemie · doi:10.1002/ange.202014898 · Cited by 24

Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson’s disease using machine learning

Ramezani, M., Mouchès, P., Yoon, E., Rajashekar, D., Ruskey, J. A., Léveillé, E., Martens, K., Kibreab, M., Hammer, T., Kathol, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84316-4 · Cited by 24

Impulse Control Disorders in Parkinson’s Disease: From Bench to Bedside

Augustine, A., Winstanley, C. A., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.654238 · Cited by 24

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease

Angius, F., Mocci, I., Ercoli, T., Loy, F., Fadda, L., Palmas, M. F., Cannas, G., Manzin, A., Defazio, G., & Carta, A. R. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11893-x · Cited by 24

Small Molecules in Parkinson’s Disease Therapy: From Dopamine Pathways to New Emerging Targets

Lee, H., Elkamhawy, A., Rakhalskaya, P., Lu, Q., Nada, H., Quan, G., & Lee, K. (2024) · Pharmaceuticals · doi:10.3390/ph17121688 · Cited by 23

REMOVED: Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2 nanowired mesenchymal stem cells and cerebrolysin

Sharma, A., Muresanu, D. F., Nozari, A., Lafuente, J. V., Sahib, S., Tian, Z. R., Buzoianu, A. D., Patnaik, R., Wiklund, L., & Sharma, H. S. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.09.010 · Cited by 23

Use of 3D Printing Techniques to Fabricate Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases

Zilinskaite, N., Shukla, R. P., & Baradokė, A. (2023) · ACS Measurement Science Au · doi:10.1021/acsmeasuresciau.3c00028 · Cited by 23

Potential convergence of olfactory dysfunction in Parkinson’s disease and COVID-19: The role of neuroinflammation

Li, H., Qian, J., Wang, Y., Wang, J., Mi, X., Qu, L., Song, N., & Xie, J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102288 · Cited by 22

Toward a biological definition of neuronal and glial synucleinopathies

Soto, C. A., Mollenhauer, B., Hansson, O., Kang, U. J., Alcalay, R. N., Standaert, D. G., Trenkwalder, C., MAREK, K. L., Galasko, D. R., & Poston, K. L. (2025) · Nature Medicine · doi:10.1038/s41591-024-03469-7 · Cited by 25

SPR immunosensor combined with Ti4+@TiP nanoparticles for the evaluation of phosphorylated alpha-synuclein level

Yin, Z., Cheng, X., Wang, G., Chen, J., Jin, Y., Tu, Q., & Xiang, J. (2020) · Microchimica Acta · doi:10.1007/s00604-020-04507-0 · Cited by 22

Potential Tear Biomarkers for the Diagnosis of Parkinson’s Disease—A Pilot Study

Acera, A., Gómez‐Esteban, J. C., Murueta‐Goyena, A., Galdós, M., Azkargorta, M., Elortza, F., Ruzafa, N., Ibarrondo, O., Pereiro, X., & Vecino, E. (2022) · Proteomes · doi:10.3390/proteomes10010004 · Cited by 25

Lewy Body-Associated Proteins A-Synuclein (a-syn) as a Plasma-Based Biomarker for Parkinson’s Disease

Zhao, X., He, H., Xiong, X., Ye, Q., Feng, F., Zhou, S., Chen, W., Xia, K., Qian, S., Yang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.869797 · Cited by 22

Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies

Huang, J., Yuan, X., Chen, L., Hu, B., Wang, H., Wang, Y., & Huang, W. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112366 · Cited by 22

Blood biomarker for Parkinson disease: peptoids

Yazdani, U., Zaman, S., Hynan, L. S., Brown, L., Dewey, R. B., Karp, D. R., & German, D. C. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.12 · Cited by 22

Understanding the influence of TLR-mediated immune system on necroptosis-induced neurodegeneration in Parkinson’s disease

Jadhav, V. S., & Khatri, D. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102872 · Cited by 22

Postural control of Parkinson’s disease: A visualized analysis based on Citespace knowledge graph

Li, Y., Zheng, J., Wu, X., Gao, W. Y., & Liu, C.-J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1136177 · Cited by 21

Redox Imbalance in Neurological Disorders in Adults and Children

Rey, F., Berardo, C., Maghraby, E., Mauri, A., Messa, L., Esposito, L., Casili, G., Ottolenghi, S., Bonaventura, E., Cuzzocrea, S., et al. (2023) · Antioxidants · doi:10.3390/antiox12040965 · Cited by 23

Lateralized microstructural changes in early-stage Parkinson’s disease in anterior olfactory structures, but not in substantia nigra

Joshi, N., Rolheiser, T. M., Fisk, J. D., McKelvey, J. R., Schoffer, K. L., Phillips, G., Armstrong, M. J., Khan, M. N., Leslie, R. A., Rusak, B., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8555-3 · Cited by 21

Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease

Ibáñez, L., Bahena, J. A., Yang, C., Dube, U., Farias, F., Budde, J., Bergmann, K., Brenner-Webster, C., Morris, J. C., Perrin, R. J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01072-8 · Cited by 20

L‐DOPA regulates α‐synuclein accumulation in experimental parkinsonism

Deffains, M., Canron, M., Teil, M., Li, Q., Dehay, B., Bézard, E., & Fernagut, P. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12678 · Cited by 21

Current Approaches and Tools Used in Drug Development against Parkinson’s Disease

Koszła, O., Stępnicki, P., Zięba, A., Grudzińska, A., Matosiuk, D., & Kaczor, A. A. (2021) · Biomolecules · doi:10.3390/biom11060897 · Cited by 25

Lewy Body Dementias: A Coin with Two Sides?

Milán-Tomás, Á., Fernández‐Matarrubia, M., & Rodríguez-Oroz, M. C. (2021) · Behavioral Sciences · doi:10.3390/bs11070094 · Cited by 24

Bionic Dormant Body of Timed Wake-Up for Bacteriotherapy in Vivo

Guo, M., Yang, C., Li, B., Cheng, S., Guo, Q., Ming, D., & Zheng, B. (2022) · ACS Nano · doi:10.1021/acsnano.1c08377 · Cited by 20

α-Synuclein Conformational Plasticity: Physiologic States, Pathologic Strains, and Biotechnological Applications

Li, A., Rastegar, C. T., & Mao, X. (2022) · Biomolecules · doi:10.3390/biom12070994 · Cited by 20

Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study

Koníčková, D., Menšíková, K., Klíčová, K., Chudáčková, M., Kaiserová, M., Vranová, H. P., Otruba, P., Nevrlý, M., Hluštík, P., Hényková, E., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15944 · Cited by 19

Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson’s disease

Giri, B., Seamon, M., Banerjee, A., Chauhan, S., Purohit, S. B., Morgan, J. C., Baban, B., & Wakade, C. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00735-2 · Cited by 19

Intrinsically disordered proteins (IDPs) studied by EPR and in-cell EPR

Weickert, S., Cattani, J., & Drescher, M. (2018) · Royal Society of Chemistry eBooks · doi:10.1039/9781788013888-00001 · Cited by 18

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity

Gupta, V. R., Salim, S., Hmila, I., Vaikath, N. N., Sudhakaran, I. P., Ghanem, S. S., Majbour, N. K., Abdulla, S. A., Emara, M. M., Abdesselem, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65035-8 · Cited by 18

α-Synuclein aggregates inhibit ESCRT-III through sequestration and collateral degradation

Sitron, C. S., Trinkaus, V. A., Galesic, A., Garhammer, M., Yuste‐Checa, P., Dransfeld, U., Feigenbutz, D., Zhang, J., Ivashko, L., Dudanova, I., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.08.022 · Cited by 19

Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers

Fan, Q., Gao, Y., Mazur, F., & Chandrawati, R. (2021) · Biomaterials Science · doi:10.1039/d1bm01226f · Cited by 17

From protein biomarkers to proteomics in dementia with Lewy Bodies

Tsamourgelis, A., Swann, P., Chouliaras, L., & O'Brien, J. T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101771 · Cited by 18

Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study

Liu, G., Tian, C., Gao, L., Cao, Z., & Feng, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.09.012 · Cited by 17

Saliva Diagnosis as a Disease Predictor

McGeer, P. L., Lee, M., Kennedy, K., & McGeer, E. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020377 · Cited by 17

Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease

Fernández‐Espejo, E., de Fonseca, F. R., Suárez, J., TOLOSA, E. S., Vilas, D., Aldecoa, I., Berenguer, J., & Damas-Hermoso, F. (2021) · Antioxidants · doi:10.3390/antiox10050715 · Cited by 17

Distribution of α-Synuclein Aggregation in the Peripheral Tissues

Li, Y., Zhou, T.-T., Zhang, Y., Chen, N., & Yuan, Y. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03586-0 · Cited by 18

Early detection of Parkinson’s disease through multiplex blood and urine biomarkers prior to clinical diagnosis

Gao, S., Wang, Z., Huang, Y., Yang, G., Wang, Y., Yi, Y., Zhou, Q., Jian, X., Zhao, G., Li, B., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00888-2 · Cited by 20

Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinson’s Disease

Ghit, A., & Deeb, H. E. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-01984-1 · Cited by 15

Vitamin B6, B12 and folate modulate deregulated pathways and protein aggregation in yeast model of Huntington disease

Pradhan, S. S., Rao, K. R., Manjunath, M., Saiswaroop, R., Patnana, D. P., Kanikaram, S. P., Choudhary, B., & Sivaramakrishnan, V. (2023) · 3 Biotech · doi:10.1007/s13205-023-03525-y · Cited by 16

Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson’s disease

Nam, D., Kim, A., Han, S. J., Lee, S.-I., Park, S., Seol, W., Son, I., & Ho, D. H. (2021) · Animal Cells and Systems · doi:10.1080/19768354.2021.1883735 · Cited by 16

Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo

Braczynski, A. K., Sevenich, M. M., Gering, I., Kupreichyk, T., Agerschou, E. D., Kronimus, Y., Habib, P., Stoldt, M., Willbold, D., Schulz, J. B., et al. (2022) · Biomolecules · doi:10.3390/biom12030469 · Cited by 17

Metformin improves depressive-like behavior in experimental Parkinson’s disease by inducing autophagy in the substantia nigra and hippocampus

Mendonça, I. P., de Paiva, I. H. R., Duarte-Silva, E. P., de Melo, M. G., da Silva, R. S., do Nascimento, M. I. X., & Peixoto, C. A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01043-6 · Cited by 17

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Emerging Therapies for Neurodegenerative Diseases

Chen, P., Wang, F., Ling, B., Zhu, Y., Lin, H., Huang, J., & Wang, X.-L. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s526945 · Cited by 16

Salivary Exosomes in Health and Disease: Future Prospects in the Eye

Liu, A., Hefley, B. S., Escandon, P., Nicholas, S. E., & Karamichos, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076363 · Cited by 16

The long non-coding RNA BDNF-AS induces neuronal cell apoptosis by targeting miR-125b-5p in Alzheimer’s disease models

Ren, H., Qiu, W., Zhu, B., Li, Q., Peng, C., & Chen, X. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/168241 · Cited by 15

Microglial exosomes in paraquat-induced Parkinson's disease: Neuroprotection and biomarker clues

Wu, J., Shao, W., Liu, X., Zheng, F., Wang, Y., Cai, P., Guo, Z., Hu, H., Yu, G., Guo, J., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124035 · Cited by 16

Identification and validation of key molecules associated with humoral immune modulation in Parkinson’s disease based on bioinformatics

Xing, N., Dong, Z., Wu, Q., Kan, P., Han, Y., Cheng, X., & Zhang, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948615 · Cited by 14

Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson’s Model

Lai, I., Porcu, A., Romoli, B., Keisler, M. N., Manfredsson, F. P., Powell, S. B., & Dulcis, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044204 · Cited by 14

Erythrocytic alpha-synuclein as potential biomarker for the differentiation between essential tremor and Parkinson’s disease

Yu, Z., Liu, G., Zheng, Y., Huang, G., & Feng, T. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1173074 · Cited by 14

Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis

Taneva, S. G., Todinova, S. J., & Andreeva, T. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814296 · Cited by 17

Development of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation

Battista, V. D., & Hey‐Hawkins, E. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.02.005 · Cited by 14

Polymer-Based Electrochemical Sensors for the Diagnosis of Neurodegenerative Diseases

Zhang, Q., Zhao, G., Wang, S., Song, Y., & Sun, Y. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01570-0 · Cited by 17

An innovative transportable immune device for the recognition of α-synuclein using KCC-1- nPr -CS 2 modified silver nano-ink: integration of pen-on-paper technology with biosensing toward early-stage diagnosis of Parkinson's disease

Saadati, A., Baghban, H. N., Hasanzadeh, M., & Shadjou, N. (2024) · RSC Advances · doi:10.1039/d3ra07058a · Cited by 13

Alpha-synuclein alterations in red blood cells of peripheral blood after acute ischemic stroke.

Wu, Z., Li, X., Zeng, M., Qiu, H., Feng, H., Xu, X.-N., Yu, S., & Wu, J. (2019) · Europe PMC (PubMed Central) · Cited by 13

Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease

Chelpin, M. V. E., Söderberg, L., Fälting, J. M., Möller, C., Giorgetti, M., Constantinescu, R., Blennow, K., Zetterberg, H., & Höglund, K. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202141 · Cited by 13

Pramipexole attenuates 6-OHDA-induced Parkinson’s disease by mediating the Nurr1/NF-κB pathway

Gao, H., Wang, D., Wang, Y., Mao, J.-P., Jiang, S., & Yang, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06343-8 · Cited by 13

Identification of α-Synuclein Proaggregator: Rapid Synthesis and Streamlining RT-QuIC Assays in Parkinson’s Disease

Takada, F., Kasahara, T., Otake, K., Maru, T., Miwa, M., Muto, K., Sasaki, M., Hirozane, Y., Yoshikawa, M., & Yamaguchi, J. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00138 · Cited by 12

Cannabidivarin alleviates α‐synuclein aggregation via DAF ‐16 in Caenorhabditis elegans

Wang, F., Jin, T., Li, H., Long, H., Liu, Y., Jin, S., Lu, Y., Peng, Y., Liu, C., Zhao, L., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200278rr · Cited by 12

Combined diagnosis for Parkinson's disease via gait and eye movement disorders

Li, H., Ma, W., Li, C., He, Q., Zhou, Y., & Xie, A. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106979 · Cited by 12

How do HCN channels play a part in Alzheimer's and Parkinson's disease?

Zhang, Z., Luo, X., Jiang, L., Wu, H., & Tan, Z. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102436 · Cited by 12

Exploration of the α-syn/T199678/miR-519–3p/KLF9 pathway in a PD-related α-syn pathology

Lin, D., Li, Y., Huang, K., Chen, Y., Jing, X., Liang, Y., Bu, L.-L., Peng, S., Zeng, S., Asakawa, T., et al. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.05.012 · Cited by 12

Traffic-Related Air Pollution and Neurodegenerative Diseases: Epidemiological and Experimental Evidence, and Potential Underlying Mechanisms

Costa, L. G. (2017) · Advances in neurotoxicology · doi:10.1016/bs.ant.2017.07.001 · Cited by 12

Transmission Electron Microscopy-based characterization of Extracellular Vesicles from plasma and serum from Parkinson´s Disease patients

Weiß, A., Meissner, A. F., Boros, F. A., Regensburger, M., Taudte, R. V., Matamoros‐Angles, A., Arnold, P., & Zunke, F. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02383-w · Cited by 11

Eye movement disorders: A new approach to preliminary screening of Parkinson’s disease

Li, H., Li, C., Ma, W., Qin, K., Wang, Z., Hou, B., & Xie, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.023 · Cited by 11

Use of skin advanced glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases

Yamashita, H., Fukushima, E., Shimomura, K., Hirose, H., Nakayama, K., Orimo, N., Mao, W., Katsuta, N., Nishimon, S., & Ohnuma, T. (2020) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1824 · Cited by 11

Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease

Hong, X., Zheng, Y., Hou, J., Jiang, T., Lu, Y., Wang, W., Zhou, S., Ye, Q., Xie, C., & Li, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1369014 · Cited by 10

Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease

Lin, W., Lee, P., Lu, C., Lin, C., & Chou, K. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7171 · Cited by 11

Parkinson’s Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma

Surguchov, A. P. (2016) · Brain Sciences · doi:10.3390/brainsci6020017 · Cited by 10

Neuronal Vulnerability to Degeneration in Parkinson’s Disease and Therapeutic Approaches

Sharma, T., Kumar, R., & Mukherjee, S. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230426155432 · Cited by 9

Gut Microbiome as a Source of Probiotic Drugs for Parkinson’s Disease

Poluektova, E. U., Stavrovskaya, A. V., Pavlova, A. K., Yunes, R. А., Марсова, М. В., Koshenko, T. A., Illarioshkin, S. N., & Даниленко, В. Н. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199290 · Cited by 13

Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease

Wang, L., & Zhang, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00354 · Cited by 9

Prognostischer und differenzialdiagnostischer Stellenwert der Liquordiagnostik bei neurodegenerativen Demenzerkrankungen

Haußmann, R., Homeyer, P., Brandt, M. D., & Donix, M. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01339-6 · Cited by 9

Neuroprotective effects of isatin and afobazole in rats with rotenone-induced Parkinsonism are accompanied by increased brain levels of Triton X-100 soluble alpha-synuclein

Бунеева, О. А., Капица, И. Г., Zgoda, V. G., & Medvedev, A. E. (2023) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20236905290 · Cited by 9

One-Pot Radiosynthesis of [18F]Anle138b—5-(3-Bromophenyl)-3-(6-[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole—A Potential PET Radiotracer Targeting α-Synuclein Aggregates

Orlovskaya, V. V., Fedorova, O. S., Viktorov, N. B., Ваулина, Д. Д., & Красикова, Р. Н. (2023) · Molecules · doi:10.3390/molecules28062732 · Cited by 9

Accumulation of α-synuclein in hepatocytes in nonalcoholic steatohepatitis and its usefulness in pathological diagnosis

Kakimoto, T., Hosokawa, M., Ichimura‐Shimizu, M., Ogawa, H., Miyakami, Y., Sumida, S., & Tsuneyama, K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154525 · Cited by 9

Unequivocal Biomarker for Parkinson’s Disease: A Hunt that Remains a Pester

Sarkar, A., Rawat, N., Sachan, N., & Singh, M. P. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00080-4 · Cited by 9

The Diagnostic Potential of Amyloidogenic Proteins

Jin, Y., Vadukul, D. M., Gialama, D., Ge, Y., Thrush, R. J., White, J. T., & Aprile, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084128 · Cited by 9

Rumex japonicus Houtt. Protects Dopaminergic Neurons by Regulating Mitochondrial Function and Gut–Brain Axis in In Vitro and In Vivo Models of Parkinson’s Disease

Kim, H.-Y., Bae, C., Kim, J., Lee, Y., Jeon, H., Kim, H., & Kim, S. (2022) · Antioxidants · doi:10.3390/antiox11010141 · Cited by 10

Cognitive disorders: Potential astrocyte-based mechanism

Li, S., Chen, Y., & Chen, G. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111181 · Cited by 9

Unveiling the Cutting Edge: Recent Developments in α-Synuclein Nano-biosensor Technology for Precision Diagnosis of Parkinson’s Disease

Shreshtha, R., Mulukutla, A., Deb, V. K., Chauhan, N., & Jain, U. (2025) · BioNanoScience · doi:10.1007/s12668-024-01659-8 · Cited by 8

Sink or swim: Does a worm paralysis phenotype hold clues to neurodegenerative disease?

Rodriguez, P., & Blakely, R. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31125 · Cited by 7

Therapeutic potential of Coumarin-polyphenolic acid hybrids in PD: Inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation

Wang, Z., Zhang, W., Xing, L.-Z., Zhao, Y., Xu, J. P., & Zhang, Y. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129618 · Cited by 8

Tandem mass spectrometric analysis of novel caffeine scaffold‐based bifunctional compounds for Parkinson's disease

Nwabufo, C. K., El‐Aneed, A., & Krol, E. S. (2019) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8540 · Cited by 8

Recipient Reaction and Composition of Autologous Sural Nerve Tissue Grafts into the Human Brain

Colvett, I., Gilmore, A., Guzman, S. J., Ledreux, A., Quintero, J. E., Ginjupally, D. R., Gurwell, J. A., Slevin, J. T., Guduru, Z., Gerhardt, G. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196121 · Cited by 8

The application of weighted gene co-expression network analysis and support vector machine learning in the screening of Parkinson’s disease biomarkers and construction of diagnostic models

Cai, L., Tang, S., Liu, Y., Zhang, Y., & Yang, Q. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1274268 · Cited by 7

Experimental Parkinson models and green chemistry approach

AKYAZI, Ö., Korkmaz, D., & Cevher, Ş. C. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115092 · Cited by 7

Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults

Boström, E., Bachhav, S. S., Xiong, H., Zadikoff, C., Li, Q., Cohen, E. B., Dreher, I., Torrång, A., Osswald, G., Moge, M., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6103 · Cited by 7

Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease

Thakur, J., & Godad, A. P. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123376 · Cited by 7

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers

Tönges, L., Kwon, E. H., & Klebe, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.822949 · Cited by 9

Distribution and synaptic organization of substance P-like immunoreactive neurons in the mouse retina

Wang, F., Zhong, W., Yang, Q., Zhao, W., Liu, X., Rao, B., Lin, X., & Zhang, J. (2023) · Brain Structure and Function · doi:10.1007/s00429-023-02688-x · Cited by 7

Synucleinopathies: Intrinsic and Extrinsic Factors

Lomeli-Lepe, A. K., Castañeda‐Cabral, J. L., & López‐Pérez, S. J. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01154-z · Cited by 6

Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological α-Synuclein in Parkinson’s Disease Patients

Schlichtmann, B. W., Kondru, N. C., Hepker, M., Kanthasamy, A. G., Anantharam, V., John, M., Ban, B., Mallapragada, S. K., & Narasimhan, B. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00461 · Cited by 7

miR-101-3p Contributes to α-Synuclein Aggregation in Neural Cells through the miR-101-3p/SKP1/PLK2 Pathway

Zhang, M., Liu, W., Zhang, Q., & Hu, H. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/6147434 · Cited by 7

Role and Diagnostic Significance of Apolipoprotein D in Selected Neurodegenerative Disorders

Kolanek, A., Cemaga, R., & Maciejczyk, M. (2024) · Diagnostics · doi:10.3390/diagnostics14242814 · Cited by 6

Neuroinflammation as an Integral Component of Neurodegeneration in Parkinson's Disease

Sayfitdinkhuzhaev, Z. F., Zhukova, N., & Baidanova, A. N. (2024) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2024-4-4-26-33 · Cited by 6

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

Xing, V., Biggar, K. K., Ferguson, S. S. G., & Hayley, S. P. (2024) · Molecular Brain · doi:10.1186/s13041-023-01074-2 · Cited by 6

The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson’s Disease

He, Q., Zhang, S., Wang, J., Ma, T., Ma, D., Wu, L., Zhou, M., Zhao, L., Chen, Y., Liu, J., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04020-y · Cited by 6

Alpha-synuclein as a Biomarker in Parkinson’s Disease: Diagnostic Methods and Clinical Relevance

Yermagambetova, A. P., & Khamidulla, A. (2025) · West Kazakhstan Biomedicine Journal · doi:10.4103/wkbj.wkbj_2_26

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease

Du, T., Wang, L., Liu, W., Zhu, G., Chen, Y., & Zhang, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.645996 · Cited by 41

Alpha-Synuclein in bio fluids and tissues as a potential biomarker for Parkinson’s disease

Parsons, R., Legido‐Quigley, C., Chang, R., Han, P., Hiew, K., & Shah, A. K. (2017) · The HKU Scholars Hub (University of Hong Kong)

Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough

Ganguly, U., Singh, S., Pal, S., Prasad, S., Agrawal, B. K., Saini, R. V., & Chakrabarti, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.702639 · Cited by 139

α-Synuclein Biomarkers for Parkinson's DiseasePreprint

Lodge, A., & Agin‐Liebes, J. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041944 · Cited by 3